Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Terumi Murakami"'
Autor:
Ruruka Imaizumi, Tomoko Yamamoto, Kenta Masui, Keiko Ishigaki, Takatoshi Sato, Terumi Murakami, Minobu Shichiji, Kumiko Ishiguro, Atsushi Kurata
Publikováno v:
Human Pathology Reports, Vol 37, Iss , Pp 300759- (2024)
Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy, but the spinal cord is rarely examined. Here we report a case of DMD with interesting spinal cord findings. In a 37-year-old man with DMD accompanied by hypoxic encephal
Externí odkaz:
https://doaj.org/article/b9de0ba15b014307b0dbe43e1b23f6a4
Autor:
Terumi Murakami, Takatoshi Sato, Michiru Adachi, Kumiko Ishiguro, Minobu Shichiji, Hisateru Tachimori, Satoru Nagata, Keiko Ishigaki
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Although there is only symptomatic treatment for Fukuyama congenital muscular dystrophy (FCMD), several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have been conducted
Externí odkaz:
https://doaj.org/article/06c892f6d72244d78ed0b39a40c65946
Autor:
Terumi Murakami, Takatoshi Sato, Michiru Adachi, Kumiko Ishiguro, Minobu Shichiji, Hisateru Tachimori, Satoru Nagata, Keiko Ishigaki
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/c9baea1ccf06425b8a3d83ecae2d5769
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-13 (2018)
Abstract Background Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of ra
Externí odkaz:
https://doaj.org/article/f0317a32d78c4a04ae9de89a824a9d57
Autor:
M. Shichiji, Aya Matsuo, Satoru Nagata, Michiru Adachi, Terumi Murakami, Masaya Zushi, Megumi Hirose, K. Ishiguro, Keisuke Goto, Takatoshi Sato, Keiko Ishigaki, Makiko Osawa, Izumi Kondo, Tetsuo Ikai
Publikováno v:
Brain and Development. 42:383-388
Objectives The objective of this study was to confirm the validity of a short form of gross motor function measure for Fukuyama congenital muscular dystrophy (GMFM for FCMD). Methods This study is a case series and was conducted at the Tokyo Women’
Autor:
Michiru Adachi, Hisateru Tachimori, S. Nagata, Takatoshi Sato, M. Shichiji, K. Ishiguro, Terumi Murakami, Keiko Ishigaki
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Background: Although a fundamental treatment for Fukuyama congenital muscular dystrophy (FCMD) is not developed yet, several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have be
Autor:
Tomoka Uchiyama, Takatoshi Sato, Terumi Murakami, Satoshi Kuru, T. Nakayama, Ayako Hattori, Keiko Ishigaki
Publikováno v:
Neuromuscular Disorders. 29:671-677
We investigated the usefulness of segmental multifrequency bioelectrical impedance analyses (MBIA) for assessing muscle involvement in Duchenne muscular dystrophy (DMD) patients. Bioelectrical impedance data of the upper arm, thigh, and lower leg wer
Autor:
Makiko Osawa, Ikuko Kato, Keiko Ishigaki, Kayoko Saito, Makoto Funatsuka, Satoru Nagata, M. Shichiji, Terumi Murakami, Takatoshi Sato, K. Ishiguro, Kiyonobu Ishizuka
Publikováno v:
Brain and Development. 41:43-49
Background The leading cause of death in patients with Fukuyama congenital muscular dystrophy (FCMD) is congestive heart failure or respiratory dysfunction, which is same as that in Duchenne muscular dystrophy (DMD). Recent studies reported that rena
Autor:
Harumasa Nakamura, Madoka Mori-Yoshimura, Chikoto Ihara, Terumi Murakami, Hisanobu Kaiya, Makiko Osawa, Keiko Ishigaki, En Kimura, Takatoshi Sato, Tatsushi Toda, Mariko Taniguchi-Ikeda, Kazushi Maruo
Publikováno v:
Neuromuscular Disorders. 28:885-893
Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of muscular dystrophy in the Japanese population and is caused by mutations in the fukutin (FKTN) gene. In 2011, the Japan Muscular Dystrophy Association (JMDA) developed a
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-13 (2018)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases
Background Exon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the United States in 2016. To date, no systematic reviews or meta-analyses of randomized